Petrovax has announced the expansion of its export potential and the consideration of new markets for medicines and vaccines. At CPHI Worldwide-2021, the international pharmaceutical industry exhibition held on November 9 to 11 in Milan, the Russian pharmaceutical manufacturer received more than 70 offers from potential partners from Eastern Europe, the Middle East and Latin America.
According to the company’s press service, following the negotiations, Petrovax intends to start cooperating with a number of potential suppliers of biotechnological drugs, as well as organize inspections of production sites of selected companies to check their compliance with international GMP standards.
The company’s strategy involves further development of both the vaccine direction and its original product portfolio, as well as the expansion of the OTC portfolio. And Petrovax is ready to invest in projects aimed at the treatment of socially significant diseases, including cancer, autoimmune diseases, etc.
According to Dmitry Pasechnik, Petrovax’s Director of Biotechnology Products Sales and Export, today foreign players perceive Russia as a sales market for different categories of drugs: OTC and Rx, biologically active supplements, as well as medical devices. At the same time, many foreign companies are looking for partners to localize their own developments.
As it became known earlier, Petrovax has begun work on the creation of a coronavirus vaccine.